Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease

First Posted Date
2016-12-06
Last Posted Date
2021-01-13
Lead Sponsor
Asan Medical Center
Target Recruit Count
120
Registration Number
NCT02982850
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

PREVENTion of Clot in Orthopaedic Trauma

First Posted Date
2016-12-06
Last Posted Date
2024-05-14
Lead Sponsor
Major Extremity Trauma Research Consortium
Target Recruit Count
12424
Registration Number
NCT02984384
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

University of Arizona, Tucson, Arizona, United States

🇺🇸

MetroHealth Medical Center, Cleveland, Ohio, United States

and more 18 locations

Rivaroxaban or Aspirin for Biological Aortic Prosthesis

First Posted Date
2016-11-29
Last Posted Date
2018-06-27
Lead Sponsor
Christian Torp-Pedersen
Target Recruit Count
1000
Registration Number
NCT02974920
Locations
🇩🇰

Aalborg University Hospital, Aalborg, Denmark

🇩🇰

Odense University Hospital, Odense, Denmark

🇩🇰

Rigshospitalet, Copenhagen, Denmark

and more 1 locations

PPARGC1β and CNTN4 Genotype Aspirin Study

Phase 4
Conditions
Interventions
First Posted Date
2016-11-22
Last Posted Date
2016-11-22
Lead Sponsor
Royal College of Surgeons, Ireland
Target Recruit Count
160
Registration Number
NCT02970604
Locations
🇮🇪

Royal College of Surgeons in Ireland, Dublin, Ireland

Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2016-11-17
Last Posted Date
2018-05-18
Lead Sponsor
University of Michigan
Target Recruit Count
9
Registration Number
NCT02966002
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma

First Posted Date
2016-11-17
Last Posted Date
2023-10-31
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
81
Registration Number
NCT02965703
Locations
🇺🇸

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Efficacy and Safety of Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk

First Posted Date
2016-11-09
Last Posted Date
2016-11-09
Lead Sponsor
Chuncheon Sacred Heart Hospital
Target Recruit Count
1500
Registration Number
NCT02960126

Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients

First Posted Date
2016-10-14
Last Posted Date
2016-10-14
Lead Sponsor
Kangbuk Samsung Hospital
Target Recruit Count
116
Registration Number
NCT02933788

Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate in STEMI Patients

First Posted Date
2016-10-11
Last Posted Date
2016-10-11
Lead Sponsor
Fundacion Investigacion Interhospitalaria Cardiovascular
Target Recruit Count
60
Registration Number
NCT02929888
Locations
🇪🇸

Fundacion, Madrid, Spain

© Copyright 2024. All Rights Reserved by MedPath